SCHEDULE: Nan Fung Group Reduces Oculis Stake to 4.9%

Nan Fung Group Holdings Limited and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.9% in Oculis Holding AG ordinary shares.

Summary

• Nan Fung Group Holdings Limited and its affiliated entities (including NF Investment Holdings Limited, Nan Fung Life Sciences Holdings Limited, NFLS Platform Holdings Limited, NFLS Beta Limited, Pivotal Life Sciences Holdings Limited, Pivotal Partners Ltd, Pivotal bioVenture Partners Fund I U.G.P. Ltd., Pivotal bioVenture Partners Fund I G.P., L.P., and Pivotal bioVenture Partners Fund I, L.P.) collectively beneficially own 2,815,476 ordinary shares of Oculis Holding AG.
• This aggregate ownership represents 4.9% of Oculis Holding AG's outstanding ordinary shares, based on 57,169,475 shares outstanding as of October 31, 2025.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing, specifically a reduction in stake to below the 5% threshold.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Oculis Holding AG.

Sentiment

Score: 4

Explanation: The reduction in a significant investor's stake to below 5% is generally perceived as a negative signal, potentially indicating a lack of conviction or a strategic exit, even if the filing itself is purely factual.

Positives

• The filing indicates a passive investment stance, with no intent to influence control, which can be seen as a stable, non-activist shareholder presence.

Negatives

• The reduction in beneficial ownership to below 5% could be interpreted by some investors as a decrease in conviction or a strategic divestment by a significant shareholder.

Risks

• The reduction in ownership by a major investor group could signal potential concerns about the company's future performance or valuation, although the filing itself does not provide reasons for the change.

Future Outlook

NA

Industry Context

This filing reflects a change in a significant investor's stake in Oculis Holding AG, a company likely in the biotechnology or pharmaceutical sector given its name and the 'Life Sciences' entities involved. Such changes in ownership by venture capital or life sciences investment groups are common as companies mature or investment strategies evolve, often reflecting portfolio rebalancing or a shift in investment thesis.

Related Party Transactions

• The filing details the hierarchical ownership structure within the Nan Fung Group, showing how various entities (e.g., NFLS Beta, Pivotal) are ultimately controlled by Nan Fung Group Holdings Limited, clarifying the relationships among the reporting persons.

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by Nan Fung Group as a negative signal, potentially leading to downward pressure on the stock price.
• Management: Could face questions regarding the reasons for the reduction in a significant investor's stake.

Key Dates

Recommendation

The reduction of a significant investor's stake to below 5% by the Nan Fung Group, as disclosed in this Schedule 13G amendment, suggests a potential loss of confidence or a strategic divestment. While the filing provides no explicit reasons, such a move by a sophisticated investor group often precedes or accompanies a period of underperformance or a re-evaluation of the company's prospects. Investors should consider this as a potential negative signal and evaluate their holdings accordingly, as it may indicate a lack of conviction from a previously substantial shareholder.

Keywords

Oculis Holding AG, Nan Fung Group, Pivotal Life Sciences, SEC filing, Schedule 13G, beneficial ownership, equity stake, passive investor, investment reduction